INTRODUCTION {#s1}
============

Pancreatic cancer is an aggressive malignant tumor of digestive tract and a leading cause of deaths related to cancer worldwide \[[@R1], [@R2]\]. 85%--90% of pancreatic cancers are pancreatic ductal carcinoma, and most of which are adenocarcinoma (AC). Squamous cells do not exist in the normal pancreatic tissues, hence the pathogenesis of squamous cell carcinoma (SCC) remains unclear. Although SCC of the pancreas is rare, accounting for less than 1% of all cases of pancreatic neoplasms \[[@R3]\], incidence rates for this subtype are increasing in the past decade \[[@R4]\].

Though SCC arising in other solid tumors are proved to be chemosensitive or radiosensitive \[[@R5]\], the prognosis of SCC in pancreas is worse than other subtype of pancreatic cancer according to previous studies \[[@R4], [@R6]\]. In addition, although there are already standard treatments for pancreatic AC, the low incidence makes pancreatic SCC a mystery, and there are still no personal therapeutics against this rare pancreatic cancer type \[[@R3]\]. Therefore, exploring the characteristics of pancreatic SCC is necessary for developing targeted strategies.

Recently, a population-based study reported the epidemiology of pancreatic SCCs \[[@R4]\]. Moreover, another investigation revealed the gene expression patterns of pancreatic SCCs \[[@R6]\]. These new progressions provided important values for understanding this rare neoplasm. The rapid development of next generation sequencing (NGS) technologies has made a revolution to cancer research \[[@R7]--[@R10]\]. NGS technology has made it possible to detect the genetic variants including single-nucleotide variant (SNV) and Insertion and Deletion (InDel) throughout the human genome with the high throughput sequencing (HTS) methodologies. In addition, the formalin fixed paraffin embedded (FFPE) samples from pathological archives opened up the gate of the treasure that possessed abundant patient samples for NGS sequencing. In the present article, we perfomed Illumina paired-end sequencing after in-solution hybrid capture targeting 137 genes ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) related to somatic alterations in cancer \[[@R11]--[@R13]\], to identify the genomic characterristics of pancreatic SCC. These 137 genes include tumor suppressors, oncogenes, and prognostic markers that frequently possess mutation in cancers. The differential mutated genes have been discovered in pancreatic AC and SCC, respectively, which could give evidences for future researches on pathogenesis and treatment of pancreatic SCC.

RESULTS {#s2}
=======

Epidemiology of pancreatic SCC in Chinese population {#s2_1}
----------------------------------------------------

Recently, Makarova-Rusher OV et. al. performed the first population-based study to report on the epidemiology of primary pancreatic SCC by screening 214 patients with SCC from 2000 to 2012 in the United States \[[@R4]\]. Based on their study, SCCs accounted for only 0.2 % of pancreatic cancers in the United States. To find out this proportion in Chinese population, we screened 1033 pancreatic cancer cases in the First Affiliated Hospital of Soochow University (Suzhou, China), the Second Affiliated Hospital of Soochow University (Suzhou, China), and Renji Hospital (Shanghai, China). During December, 1998 to July, 2016, there were 405 cases diagnosed as pancreatic cancer in the First Affiliated Hospital of Soochow University, while only one of them were diagnosed as SCC and six cases were diagnosed as ASC. From August, 2008 to August, 2016, 169 patients were diagnosed as pancreatic cancer in the Second Affiliated Hospital of Soochow University, but none of them was SCC. 459 patients with pancreatic cancer were admitted to Renji Hospital during August, 2008 to August, 2016. One of them was diagnosed as pure SCC, and 16 were confirmed to be ASC. Therefore, in all these 1033 cases, only 2 were diagnosed as pure SCC, making the proportion of SCC in the screened Chinese population was only 0.19%.

Pathological confirmation of pancreatic SCC {#s2_2}
-------------------------------------------

Since there are still no comparison between genomic characterristics of pancreatic SCC and AC, we carried out high throughput sequencing (HTS) after in-solution hybrid capture by using 2 SCC, 2 ASC and 4 AC FFPE tissue samples. Before HTS, histological reconfirmation was firstly performed.

As shown in Figure [1A--1H](#F1){ref-type="fig"}, pathological examination of pancreatic SCCs and ASCs revealed various grades of differentiated cancer cells. As compared with AC, patients with SCC had poorly differentiated histology, in consisting with previous studies \[[@R4]\]. Microscopically, SCC of pancreas was characterized by irregulard infiltrative nests or sheets of polygonal cells with distinct cellular borders, intercellular bridges, eosinophilic cytoplasm, and/or focal keratin peal formation in the tumors. Microscopic examination also documented that there was no evidence of glandular differentiation in pure SCC. Besides, the tumors of SCC shared a common characteristic of chronic inflammatory change around the tumor. Histological examination identified marked infiltration of chronic inflammatory cells and fibrosis in the background of the tumor. Besides, in higher power image, we can see a prominent desmoplastic response in stroma clearly. Calcifications scattered along the duct of Wirsung was observed as well. Previous immunohistochemical study showed that the pancreatic SCC cells were positive for CK5/6, p40, p63, and CK19, which were the superior markers for SCC \[[@R5], [@R14], [@R15]\]. As shown in Figure [1I](#F1){ref-type="fig"} and [1J](#F1){ref-type="fig"}, CK5/6 and p63 were positively expressed in pancreatic SCC samples, in consisting with previous studies \[[@R5], [@R14], [@R15]\].

![Pathological reconfirmation of pancreatic SCC\
(**A**) to (**D**) histological reconfirmation of four pancreatic AC samples. (**E**) and (**F**) Histology of two pancreatic ASC samples. (**G**) and (**H**) histological reconfirmation of two pancreatic SCC samples. (**I**) Expression of CK5/6 in pancreatic SCC sample. (**J**) Expression of P63 in pancreatic SCC sample.](oncotarget-08-14620-g001){#F1}

Sequence capture of FFPE pancreatic cancer tissues {#s2_3}
--------------------------------------------------

The sequenced fastq output resulted in approximately 3.5 million reads for each of the FFPE pancreatic cancer tissues. Out of the raw reads, around 3.05 million reads for the SCCs, 2.99 millions reads for ASCs and approximately 3.03 million reads for the ACs were uniquely mapped to the human genome assembly hg19. The number of reads uniquely mapped to the target region was \~0.13 million for SCCs, \~0.16 million for ASCs and about 0.29 million for ACs. The percentage of the target region coverage was --53% for each sample of pancreatic cancer tissues (Table [1](#T1){ref-type="table"}).

###### Comparison of sequencing read data for FFPE pancreatic SCC, ASC and AC tissues

  Sample                                         Squamous Cell Carcinoma (SCC)   Adenosquamous Carcinoma (ASC)   Adenocarcinoma (AC)
  ---------------------------------------------- ------------------------------- ------------------------------- ---------------------
  Initial bases on target                        1091949                         1091949                         1091949
  Total effective reads                          3507289 ± 179140                3413500 ± 111295                3396153 ± 463643
  Total effective yield(Mb)                      336.78 ± 50.37                  355.95 ± 2.19                   389.07 ± 25.53
  Number of reads uniquely mapped to target      130133 ± 6578                   167451 ± 42792                  289486 ± 56272
  Number of reads uniquely mapped to genome      3050910 ± 149595                2995950 ± 89141                 3026670 ± 415926
  Fraction of effective bases on target          2.80% ± 0.14%                   3.55% ± 0.77%                   6.18% ± 1.01%
  Fraction of uniquely mapped on target          4.30% ± 0.00%                   5.60%±1.27%                     9.60% ± 1.49%
  Average sequencing depth on target             9.66 ± 0.50                     11.97 ± 2.87                    20.45 ± 3.58
  Mismatch rate in target region                 0.51% ± 0.04%                   0.50% ± 0.01%                   0.45% ± 0.03%
  Mismatch rate in all effective sequence        0.81% ± 0.14%                   0.87% ± 0.04%                   0.73% ± 0.07%
  Base covered on target                         583643 ± 16402                  579505 ± 9532                   575904 ± 9634
  Coverage of target region                      53.45% ± 1.48%                  53.10% ± 0.85%                  52.75% ± 0.87%
  Fraction of target covered with at least 20x   21.40% ± 1.97%                  28.40% ± 7.64%                  36.90% ± 1.45%
  Fraction of target covered with at least 10x   38.65% ± 0.21%                  39.20% ± 1.83%                  41.10% ± 0.64%
  Fraction of target covered with at least 4x    44.60% ± 0.98%                  43.75% ± 0.63%                  44.47% ± 0.81%
  Mapping rate                                   87.77% ± 14.93%                 98.54% ± 0.30%                  99.26% ± 0.20%
  Duplicate rate                                 73.71% ± 0.28%                  72.22% ± 0.78%                  69.93% ± 1.31%

SNV (single-nucleotide variant) analysis {#s2_4}
----------------------------------------

We have discovered a total of 2840 and 5369 SNVs for the two samples of SCC respectively, 4275 and 3837 SNVs for the two samples of ASC respectively, and 4354, 2888, 3442 and 3276 SNVs for the four samples of AC respectively. Approximately 9% to 18.49% detected SNVs fall into neither of the two categories: dbSNP and 1000 genome, which are the databases of SNPs (single-nucleotide polymorphisms) from normal healthy human beings (Figure [2A](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"}). Therefore, 257\~686 novel SNVs have been found in each sample of the pancreatic cancer tissues, which accounts for 9% to 18.4% of the total called SNVs from each sample (Table [2](#T2){ref-type="table"}). In addition, most of the SNVs for each sample were homozygous genotypes, only a percentage ranging from 23.11% to 32.76% was heterozygous (Table [2](#T2){ref-type="table"}). Among the total SNVs for each sample, about 6.37% to 10.53% of SNVs were detected in the coding region of genes (Table [2](#T2){ref-type="table"}). We also detected similar rate of transition to transversion among SCCs, ASCs and ACs (Table [2](#T2){ref-type="table"}). Importantly, around 69\~131 non-synonymous SNVs have been discovered in each FFPE sample (Figure [2B](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"}).

![SNV (single-nucleotide variant) analysis\
(**A**) Distribution of total SNVs for each sample in 1000 genome and dbSNP. 1000 genome and dbSNP: the number of SNVs that fall into both 1000 genome and dbSNP; 1000 genome specific: the number of SNVs that only fall into 1000 genome, not in dbSNP; dbSNP specific: the number of SNVs that only fall into dbSNP, not in 1000 genome; The SNVs that fall into neither 1000 genome nor dbSNP were considered as "novel". (**B**) Distribution of total SNVs that fall into the different categories leading to different genetic characters. Startloss: a nonsynonymous SNV that leads to the immediate elimination of start codon at the variant site; Startgain: a nonsynonymous SNV that leads to the immediate creation of start codon at the variant site; Stoploss: a nonsynonymous SNV that leads to the immediate elimination of stop codon at the variant site; Stopgain: Stoploss: a nonsynonymous SNV that leads to the immediate creation of stop codon at the variant site; Missense: a single nucleotide change that cause an amino acide change; Synonymous: a single nucleotide change that does not cause an amino acid change. (**C**) and (**D**) Gene Ontology (GO) analysis of SNVs specific in adenocarcinoma of pancreatic tissues. (C) Gene Ontology (GO): Biological process analysis; (D) Gene Ontology (GO): Molecular function analysis. (**E**) and (**F**) Gene Ontology (GO) analysis of SNVs specific in squamous cell carcinoma of pancreatic tissues. (E) Gene Ontology (GO): Biological process analysis; (F) Gene Ontology (GO): Molecular function analysis.](oncotarget-08-14620-g002){#F2}

###### Summary of single nucleotide variants (SNVs) for FFPE pancreatic SCC, ASC and AC tissues

  Sample                 Squamous Cell Carcinoma (SCC)   Adenosquamous Carcinoma (ASC)   Adenocarcinoma (AC)                                                                
  ---------------------- ------------------------------- ------------------------------- --------------------- -------------- --------------- -------------- -------------- ---------------
  Total                  2840                            5369                            4275                  3837           4354            2888           3442           3276
  1000genome and dbsnp   2323                            4194                            3257                  2833           3397            2101           2590           2492
  1000genome specific    9                               7                               6                     9              9               7              8              10
  dbSNP specific         251                             482                             342                   371            324             246            279            240
  dbSNP rate             90.63%                          87.09%                          84.19%                83.50%         85.46%          81.27%         83.35%         83.39%
  Novel                  257 (9%)                        686 (12.78%)                    670 (15.67%)          624 (16.26%)   624 (14.33%)    534 (18.49%)   565 (16.41%)   534 (16.30%)
  Hom                    2057                            4128                            3254                  2841           3194            1942           2539           2242
  Het                    783 (27.57%)                    1241 (23.11%)                   1021 (23.88%)         996 (25.95%)   1160 (26.64%)   946 (32.76%)   903 (26.23%)   1034 (31.56%)
  Synonymous             177                             198                             170                   146            186             153            166            150
  Missense               96                              126                             87                    93             102             65             82             74
  Stopgain               1                               2                               3                     0              1               1              0              0
  Stoploss               0                               0                               0                     0              0               0              0              0
  Startgain              0                               5                               0                     3              3               3              1              2
  Startloss              0                               0                               0                     0              0               0              1              0
  SIFT                   20                              20                              18                    20             22              15             13             16
  Ti/Tv                  2.2719                          2.2441                          2.4728                2.2683         2.4042          2.2633         2.332          2.3738
  dbSNP Ti/Tv            2.3691                          2.3069                          2.4908                2.2694         2.4169          2.2643         2.3477         2.4322
  Novel Ti/Tv            1.5446                          1.8824                          2.401                 2.267          2.3191          2.2561         2.2659         2.1047

In order to compare the genotype of SCC, ASC and AC, we searched for the different SNVs for the well-known pancreatic AC biomarkers (Table [3](#T3){ref-type="table"}). All these pancreatic cancer tissues possessed the same TP53 mutation site (Table [3](#T3){ref-type="table"}). Both SCC and AC samples contained KRAS mutation site (Table [3](#T3){ref-type="table"}). We have also found mutation sites of several genes exclusively existing in SCCs, including SMAD4 and IGF1R, while some other mutation sites occurred only in pancreatic ACs, such as TERT, BRCA2, FGFR1, and FGFR4 (Table [3](#T3){ref-type="table"}).

###### SNVs of major pancreatic ductal adenocarcinoma markers for SCC, ASC and AC

  Gene    Adenocarcinoma (AC)                                                                                                                                                              adenosquamous carcinoma (ASC)                                                                                  squamous cell carcinoma (SCC)
  ------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ----------------------------------------------
  KRAS    NM_033360:p.Gly12Arg                                                                                                                                                             --                                                                                                             NM_033360:p.Gly12Asp
  TP53    NM_000546:p.Pro72Arg                                                                                                                                                             NM_000546:p.Pro72Arg                                                                                           NM_000546:p.Pro72Arg
  SMAD4   --                                                                                                                                                                               NM_005359:p.Pro292Ser                                                                                          NM_005359:p.Arg496His
  TERT    NM_198253:p.Gln384Arg                                                                                                                                                            --                                                                                                             --
  IGF1R   --                                                                                                                                                                               NM_000875:p.Gly7Glu                                                                                            NM_000875:p.Pro842Ser
  BRCA2   NM_000059:p.Val2466Ala NM_000059:p.Asn372HisNM_000059:p.Asn289HisNM_000059:p.Asn991AspNM_000059:p.Thr2471SerNM_000059:p.Ile3363MetNM_000059:p.Ser3366AsnNM_000059:p.Val2466Ala   NM_000059:p.Cys315Ser NM_000059:p.Val2466AlaNM_000059:p.Asn289HisNM_000059:p.Asn991AspNM_000059:p.Asp2438Asn   NM_000059:p.Asn372His NM_000059:p.Val2466Ala
  EGFR    NM_005228:p.Arg521Lys NM_005228:p.Leu861Gln                                                                                                                                      NM_005228:p.Arg521Lys NM_005228:p.Leu861Gln                                                                    NM_005228:p.Arg521Lys
  FGFR1   NM_001174067:p.Ala392Val                                                                                                                                                         --                                                                                                             --
  FGFR4   NM_002011:p.Val10Ile NM_002011:p.Pro136LeuNM_002011:p.Gly388ArgNM_002011:p.Thr179Ala                                                                                             NM_002011:p.Pro136Leu NM_002011:p.Gly388Arg                                                                    NM_002011:p.Pro136Leu NM_002011:p.Gly388Arg

We then selected those mutated genes that did not occur in pure SCCs. A total of nine mutated genes were found in ASCs and ACs, including ABCB1, CSF1R, CYP2C18, FBXW7, ITPA, KIAA0748, SOD2, SULT1A2, ZNF142. Among these nine mutated genes, four genes (ABCB1, CYP2C18, SOD2, and ZNF142) were discovered to possess SNVs only in ACs (Table [4](#T4){ref-type="table"}). Gene Ontology (GO) analysis showed that these nine specific mutated genes were involved in the following main biological processes: regulation of oxidative stress-induced intrinsic apoptotic signaling pathway (GO:1902175) and cell death (GO:1903201) (Figure [2C](#F2){ref-type="fig"}) and in the following main molecular functions: oxygen binding (GO:0019825), drug transmembrane transporter activity (GO: 0015238) (Figure [2D](#F2){ref-type="fig"}).

###### Summary of specific mutated genes in pancreatic AC tissues

  Gene       Squamous Cell Carcinoma (SCC)   Adenosquamous Carcinoma (ASC)   Adenocarcinoma (AC)
  ---------- ------------------------------- ------------------------------- ---------------------
  ABCB1      0                               0                               2
  CSF1R      0                               1                               5
  CYP2C18    0                               0                               3
  FBXW7      0                               2                               1
  ITPA       0                               0                               2
  KIAA0748   0                               1                               3
  SOD2       0                               0                               2
  SULT1A2    0                               1                               2
  ZNF142     0                               0                               2

In addition, we also found nine genes (C7orf70, DNHD1, KPRP, MDM4, MUC6, OR51Q1, PTPRD, TCF4, and TET2) that possess no mutation in ACs. Among these nine mutated genes, four genes (DNHD1, OR51Q1, PTPRD, and TCF4) were discovered to possess SNVs exclusively in SCCs (Table [5](#T5){ref-type="table"}). The analysis of Gene Ontology (GO) discovered that these nine mutated genes were involved in the following main biological processes: histone H3K4 methylation (GO:0051568), DNA methylation (GO: 0080111) and negative regulation of cell cycle arrest (GO: 0071157) (Figure [2E](#F2){ref-type="fig"}). For the GO category of molecular functions, these nine mutated genes were mainly involved in basal transcription machinery binding (GO: 0001098), ferrous iron binding (GO:0008198) and LRR domain binding (GO: 0030275) (Figure [2F](#F2){ref-type="fig"}).

###### Summary of specific mutated genes in pancreatic SCC and ASC tissues

  Gene      Squamous Cell Carcinoma (SCC)   Adenosquamous Carcinoma (ASC)   Adenocarcinoma (AC)
  --------- ------------------------------- ------------------------------- ---------------------
  C7orf70   2                               1                               0
  DNHD1     2                               0                               0
  KPRP      1                               0                               1
  MDM4      1                               0                               0
  MUC6      2                               1                               0
  OR51Q1    2                               0                               0
  PTPRD     2                               0                               0
  TCF4      2                               0                               0
  TET2      4                               0                               0

InDel (Insertion and Deletion) analysis {#s2_5}
---------------------------------------

A total of 232\~377 InDels have been discovered for the SCC, ASC and AC of pancreatic cancers (Table [6](#T6){ref-type="table"}). A percentage of 27.15% to 32.37% detected InDels were not found in the dbSNP or 1000 genome (Table [6](#T6){ref-type="table"}, Figure [3A](#F3){ref-type="fig"}). Approximately 63\~113 novel Inserts and Deletions have been found in each sample of the pancreatic carcinoma FFPE tissues (Table [6](#T6){ref-type="table"}). In addition, from one to six framshift InDels were found in each FFPE sample (Table [6](#T6){ref-type="table"}, Figure [3B](#F3){ref-type="fig"}).

###### Summary of InDels for FFPE pancreatic SCC, ASC and AC tissues

  Sample                                             Squamous Cell Carcinoma (SCC)   Adenosquamous Carcinoma (ASC)   Adenocarcinoma (AC)                                                               
  -------------------------------------------------- ------------------------------- ------------------------------- --------------------- -------------- -------------- -------------- -------------- --------------
  Total                                              232                             377                             312                   283            327            235            263            293
  1000genome and dbsnp                               70                              113                             98                    80             118            61             84             93
  1000genome specific                                0                               4                               2                     0              1              1              1              1
  dbSNP specific                                     99                              147                             111                   113            119            101            102            119
  dbSNP rate                                         72.84%                          68.97%                          66.99%                68.20%         72.48%         68.94%         70.72%         72.35%
  Novel                                              63 (27.15%)                     113 (29.97%)                    101 (32.37%)          90 (31.80%)    89 (27.22%)    72 (30.64%)    76 (28.90%)    80 (27.30%)
  Hom                                                140 (60.34%)                    226 (59.59%)                    167 (53.53%)          154 (54.42%)   167 (51.07%)   116 (49.36%)   130 (49.43%)   151 (51.54%)
  Het                                                92                              151                             145                   129            160            119            133            142
  Frameshift                                         2                               3                               3                     6              2              3              1              2
  Non-frameshift Insertion                           0                               1                               0                     0              0              0              0              0
  Non-frameshift Deletion                            0                               1                               0                     0              0              0              0              0
  Non-frameshift codon substitution                  0                               0                               0                     0              0              0              0              0
  Non-frameshift codon substitution plus Insertion   0                               1                               0                     0              1              0              0              0
  Non-frameshift codon substitution plus Deletion    2                               0                               1                     0              1              0              1              2
  Stopgain                                           0                               0                               0                     0              0              0              0              0
  Stoploss                                           0                               0                               0                     0              0              0              0              0
  Startgain                                          0                               0                               0                     0              0              0              0              0
  Startloss                                          0                               0                               0                     0              0              0              0              0

![The distribution of InDels detected in pancreatic cancer tissues\
(**A**) Distribution of InDels for each sample in 1000 genome and dbSNP. 1000 genome and dbSNP: the number of InDels that fall into both 1000 genome and dbSNP; 1000 genome specific: the number of InDels that only fall into 1000 genome, not in dbSNP; dbSNP specific: the number of InDels that only fall into dbSNP, not in 1000 genome; The InDels that fall into neither 1000 genome nor dbSNP were considered as "novel". (**B**) Distribution of total InDels that fall into the different categories leading to different genetic characters. Startloss: a nonframeshift insertion/deletion/substitution that leads to the immediate elimination of start codon at the variant site; Startgain: a nonframeshift insertion/deletion/substitution that leads to the immediate creation of start codon at the variant site; Stoploss: a nonframeshift insertion/deletion/substitution that leads to the immediate elimination of stop codon at the variant site; Stopgain: a nonframeshift insertion/deletion/substitution that leads to the immediate creation of stop codon at the variant site; Non-frameshift codon substitution plus Deletion: a codon substitution of one or more nucleotides plus a deletion of 3 or multiples of 3 nucleotides that do not cause frameshift changes in protein coding sequence; Non-frameshift codon substitution plus Insertion: a codon substitution of one or more nucleotides plus an insertion of 3 or multiples of 3 nucleotides that do not cause frameshift changes in protein coding sequence; Non-frameshift codon substitution: a codon substitution of one or more nucleotides that does not cause frameshift changes in protein coding sequence; Non-frameshift Deletion: a deletion of 3 or multiples of 3 nucleotides that do not cause frameshift changes in protein coding sequence; Non-frameshift Insertion: an insertion of 3 or multiples of 3 nucleotides that do not cause frameshift changes in protein coding sequence; Frameshift: an insertion/deletion/substitution of one or more nucleotides that cause frameshift changes in protein coding sequence.](oncotarget-08-14620-g003){#F3}

Gene expression characteristics of pancreatic SCC {#s2_6}
-------------------------------------------------

Besides investigation on the genomic level, we also evaluated the gene expression characteristics of pancreatic SCC. Based on data provided by Peter Bailey et al. \[[@R6]\], expressions of 12633 genes were found to be changed in pancreatic SCCs according to normal pancreas tissues, reaching more than 1.5-fold \[[@R6]\]. And 8470 of them were found to be up- or down-regulated by over 2-fold \[[@R6]\].

To illustrate a more detailed cell signaling transduction pathway network, these 12633 genes were subjected to KEGG pathway assay. As shown in [Supplementary Table 2](#SD2){ref-type="supplementary-material"} and Figure [4](#F4){ref-type="fig"}, these genes participated in multiple pathways in cancer (PATH:05200), including PI3K-Akt signaling pathway, Focal adhesion, MAPK signaling pathway, Ras signaling pathway, VEGF signaling pathway, TGF-β signaling pathway, TNF signaling pathway, Cell adhesion molecules (CAMs), Tight junction, Wnt signaling pathway, Notch signaling pathway, Hedgehog signaling pathway, mTOR signaling pathway, et al.. Since these pathways are involved in malignant biological behaviors, such as metastasis, proliferation, evading apoptosis, angiogenesis, insensitive to anti-growth signals, resistant to chemotherapy, and stemness maintaining, et al., the aberrant expression of these genes could take part in the development and progression of pancreatic SCCs.

![KEGG pathway assay of genes differentially expressed in pancreatic SCCs\
(**A**) Top pathways identifiedby using KEGG pathway assay (*P* \< 0.01). (**B**) Genes involved in the cell signaling transduction of pathways in cancer (PATH:05200).](oncotarget-08-14620-g004){#F4}

DISCUSSION {#s3}
==========

Pancreas is an organ without squamous cell differentiation in its normal state. However, parenchymal squamous metaplasia is commonly detected in pancreatic specimens, and can be detected in 17% to 48% of cases \[[@R4]\]. Despite the relatively high frequency of squamous metaplasia, pancreatic squamous cell carcinoma (SCC) is a rare primary pancreatic malignancy, accounting for 0.05--5% of all pancreatic cancers approximately \[[@R4], [@R16]--[@R20]\]. In the present study, we screened 1033 cases of pancreatic cancer in Chinese population, and identified only 2 cases of pure SCC, accounting for only 0.19% of all cases. Therefore, pancreatic SCC is a rare subtype of pancreatic cancer worldwide. The available published data on pancreatic SCC are limited, mostly presented as individual case reports or small case series studies. As a result, the characteristics of SCC remain poorly verified. It is noteworthy that, due to its rare incidence, cases about pancreatic SCC are firstly presumed to be metastatic from other primary site \[[@R21]\]. Metastatic spread of primary lung or esophageal SCC sometimes has been reported to pretend to be primary pancreatic SCC \[[@R5], [@R22]\]. However, it should be noted that metastatic SCC to the pancreas is also very rare \[[@R23]\]. So, careful exclusion is vital before we diagnose primary SCC of pancreas.

Recently, a population-based study firstly revealed the epidemiology of primary pancreatic SCC \[[@R4]\]. By screening 214 patients with SCC, Makarova-Rusher OV et al. proved that the incidence rate for primary pancreatic SCC differed by age, sex, race, and ethnicity. There was a significant increase in the age-adjusted incidence rate in men relative to women (RR of 1.6). When analyzed by race, the age-adjusted incidence rates of SCC were higher in African American relative to Caucasian (RR of 1.7). At the same time, the International Agency for Research on Cancer (IARC) has reported that in the United States, the highest rates were registered among black individuals (12--15 cases per 100,000 men and 8--10 cases per 100,000 women); these rates are \~30--50% higher than in their white counterparts \[[@R1], [@R2]\]. Increased risk was also observed for older age groups. 65 years and older patients had an RR of 141.1 relative to people younger than 40 years and 5.1 when compared with age group of 40 to 64 years old. Over time, the incidence rates for SCC varied but with a significantly overall increasing trend, and the incidence rates tripled between 2000 and 2012 in the United States. The annual percent increase of SCC was of 5.5%, while the annual percent increase of AC was only 1.4% \[[@R4]\]. Therefore, although primary pancreatic SCC is a rare neoplasm, incidence rates for this subtype are increasing.

By now, there are only twenty reported cases of pancreatic SCC (Table [7](#T7){ref-type="table"}) \[[@R5], [@R14]--[@R16], [@R18], [@R19], [@R21], [@R24]--[@R35]\], providing limited, but valuable clinical information. The clinical presentation of SCC is similar to that of AC. As the cases have been reported, thirteen patients were presented with an initial symptom of abdominal or back pain \[[@R15], [@R16], [@R18], [@R19], [@R21], [@R24], [@R27], [@R28], [@R30]--[@R32], [@R34], [@R35]\]. Rest of them were also referred with fatigue, anorexia, nausea, tarry stool, weight loss, or jaundice when found \[[@R5], [@R14], [@R16], [@R25], [@R26], [@R29], [@R33]\]. Imaging examination or laparotomy detected the mass of the pancreas and found that nine of them were in the head \[[@R5], [@R16], [@R19], [@R21], [@R25], [@R27], [@R29], [@R30], [@R32]\], three in the body \[[@R16], [@R18], [@R35]\], four in the tail \[[@R14], [@R28], [@R31], [@R34]\], and three in both body and tail \[[@R24], [@R26], [@R33]\]. The remaining one was not mentioned, since the patient was unresectable with liver metastasis at diagnosis \[[@R15]\]. Fifteen of them endured resection. Seven of the resected tumors were composed of moderately differentiated SCC \[[@R16], [@R19], [@R26], [@R27], [@R30], [@R33], [@R35]\]. Three were well differentiated \[[@R18], [@R28], [@R29]\]. One was moderately to poorly differentiated \[[@R31]\]. Another one was poorly differentiated SCC \[[@R21]\]. The rest of the cases were not mentioned. We also noticed that some specific markers might be useful for SCC diagnosis and prognosis evaluation. Most cases reported that the serum SCC-related antigen (SCC-Ag) level was often elevated, and decreased markedly after resection \[[@R33]\]. Previous studies also find that CD44 and its variants were good markers of squamous epithelial differentiation in several types of normal epithelium and tumors. These markers can distinguish areas of well- to moderately-differentiated squamous elements from AC elements. However, poorly differentiated tumors show an inconsistent staining pattern with CD44, so it cannot be used in poorly differentiated neoplasms \[[@R36]\].

###### Reported 20 cases of pancreatic SCC in the literatures

  Author                              Age   Sex   Presenting symptom (s)                                                          Location        Size (cm)   Surgery                                                                                                                                                                      TNM                  Differentiation                              Outcome                                                                                           Treatment                                                                                                                                                            Time to death (months)
  ----------------------------------- ----- ----- ------------------------------------------------------------------------------- --------------- ----------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- -------------------------------------------- ------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------
  Kodavatiganti R et. al. \[[@R4]\]   70    M     Weight loss, generalized itching, jaundice                                      Head            4.6×4.1     Pylorus-sparing pancreaticoduodenectomy                                                                                                                                      pT4N1M0, Stage III   Not known                                    Liver metastatic after 1 months of surgery; Death                                                 Palliative chemotherapy after liver metastatic (cisplatin/5-FU)                                                                                                      8 months after surgery because of sepsis.
  Ikeda A et. al. \[[@R19]\]          79    M     Fatigue, unintentional weight loss                                              Tail            5           N/A                                                                                                                                                                          Stage IV             Not known                                    Liver metastasis at diagnosis; Death                                                              Palliative chemotherapy (S-1 100 mg/day). Four courses of S-1 tumor progressed, gemcitabine as second-line chemotherapy.                                             7 months after treatment
  De Souza AL et. al. \[[@R20]\]      61    M     Anorexia, weight loss, right upper back and stomach pain                        Not known       Not known   N/A                                                                                                                                                                          Stage IV             Not known                                    Liver metastasis at diagnosis; Death                                                              Palliative chemotherapy (gemcitabine/cisplatin every 14 days for 4 months, progressed after 8 weeks, received 5-FU/leucovorin as second-line therapy for 3 months)   11 months from treatment
  Ben Kridis W et. al. \[[@R21]\]     48    M     Epigastric pain epigastric pain                                                 Head            4.6         N/A                                                                                                                                                                          Not known            Not known                                    Death                                                                                             Chemotherapy one cycle (5-FU/cisplatin) + palliative radiotherapy                                                                                                    9 months
  Ben Kridis W et. al. \[[@R21]\]     42    M     vomiting, peri umbilical pain                                                   Body            4×3.7×3.1   Spleno-corporeo-caudal pancreatectomy                                                                                                                                        pT3N0M0, Stage IIA   Moderately differentiated (G2)               Not known                                                                                         Adjuvant chemotherapy (5-FU/leucovorin)                                                                                                                              More than 26 months
  Nikfam S et. al. \[[@R23]\]         66    F     Epigastric pain                                                                 Body            3.5×4       N/A                                                                                                                                                                          Not known            Well differentiated                          Death                                                                                             Palliative chemotherapy (gemcitabine)                                                                                                                                9 months after treatment
  Beyer KL et. al. \[[@R24]\]         33    F     Upper abdominal pain                                                            Head            10-12       Palliative bypass surgery (Roux-en-Y choledochojejunostomy and cystjejunostomy)                                                                                              Not known            Moderately differentiated (G2)               9 months post-operation, she felt well and worked daily. She had no pain and was not jaundiced.   Immunotherapeutic agents                                                                                                                                             More than 9 months
  Al-Shehri A et. al. \[[@R26]\]      48    F     Fatigue,anorexia, weight loss, nausea,vomiting, upper abdominal and back pain   Head            4.4×4.2     Palliative bypass surgery (gastrojejunostomy and choledochojejunostomy)                                                                                                      Stage IV             Poorly differentiated                        Liver metastasis at diagnosis; Death                                                              Palliative chemotherapy (carboplatin/gemcitabine)                                                                                                                    3 months
  Schultheis AM et. al. \[[@R29]\]    57    F     Postprandial epigastric pain                                                    Body and tail   5-6         Not known                                                                                                                                                                    Not known            Not known                                    Death                                                                                             Primary neoadjuvant radiochemotherapy                                                                                                                                11 months after surgery
  Kubota K et. al. \[[@R30]\]         73    F     Fatigue, appetite loss, jaundice                                                Head            8           Pancreatoduodenectomy                                                                                                                                                        Not known            Not known                                    Not known                                                                                         Not known                                                                                                                                                            Not known
  Aurello P et. al. \[[@R31]\]        58    F     Hematemesis, melena, and acute anemia, weight loss, vomiting                    Body and tail   8           Total gastrectomy, left nephroadrenalectomy, distal pancreatectomy, splenectomy, andthe left colic flexure esection+Roux-en-Y esophagojejunostomy and colocolicanastomosis   pT4N0M0, Stage III   Moderately differentiated (G2)               Not known                                                                                         Adjuvant chemotherapy (cisplatin/5-FU, two cycles)                                                                                                                   Not known
  Sears HF et. al. \[[@R32]\]         70    F     Epigastric distress, anorexia, weight loss, nauseau, vomiting                   Head            6           Palliative bypass surgery (choledochojejunostomy)                                                                                                                            Stage IV             Moderately differentiated (G2)               Porta hepatis metastasis at laparotomy; Death                                                     Radiotherapy                                                                                                                                                         6 weeks after radiotherapy
  Adachi K et. al. \[[@R33]\]         67    F     Anorexia, back pain                                                             Tail            6×6×7       Resected with a total gastrectomy, distal pancreatectomy and splenectomy                                                                                                     pT3N1M0 Stage IIB    Well differentiated (G1)                     Local recurrence after 4 months of surgery; Death                                                 Radiation therapy for local recurrence                                                                                                                               11 months after surgery
  Chen QP et. al. \[[@R34]\]          55    M     Jaundice, pale-colored stool, anorexia, weight loss                             Head            4×5×5       Pancreaticoduodenectomy,resection of the lateral wall of the portal vein and the left lobe of liver                                                                          Not known            Well-differentiated                          Death                                                                                             Not known                                                                                                                                                            10 months after surgery
  Terada T et. al. \[[@R35]\]         69    F     Abdominal pain, jaundice                                                        Head            5×5×6       Pancreaticoduodenal resection and cholecystectomy                                                                                                                            Not known            Moderately differentiated (G2)               Death                                                                                             Not known                                                                                                                                                            3 months after surgery
  Brown HA et. al. \[[@R36]\]         56    M     Back pain                                                                       Tail            6           Resected with bloc distal pancreatectomy,splenectomy, partial gastrectomy, and left adrenalectomy                                                                            pT2N0MX Stage IB     Moderately to poorly differentiated (G2-3)   Liver metastatic after 3 months of surgery; Death                                                 Chemotherapy after liver metastatic                                                                                                                                  Not known
  Rana SS et. al. \[[@R37]\]          50    M     Upper abdominal pain radiated to the back, vomiting, jaundice                   Head            Not known   Palliative bypass surgery (jejunostomy)                                                                                                                                      Not known            Not known                                    Not known                                                                                         Palliative treatment                                                                                                                                                 Not known
  Minami T et. al. \[[@R38]\]         62    M     Fatigue, fever, tarry stool                                                     Body and tail   8           Distal pancreatectomy, total gastrectomy, splenectomy, and partial colectomy                                                                                                 pT3N0M0 Stage IIA    Moderately differentiated (G2)               Not known                                                                                         Not known                                                                                                                                                            More than 16 months
  Lai LH et. al. \[[@R39]\]           76    F     Dull epigastric pain with radiation to the back, weight loss                    Tail            5           N/A                                                                                                                                                                          Stage IV             Not known                                    Liver metastasis at diagnosis                                                                     Not known                                                                                                                                                            Not known
  Bralet MP et. al. \[[@R40]\]        68    F     Abdominalpain, weight loss                                                      Body            4           Distal pancreatectomy, cholecystectomy                                                                                                                                       Not known            Moderately differentiated (G2)               Not known                                                                                         Not known                                                                                                                                                            More than 8 months

Surgery is still the only relatively efficient cure for this rare but virulent disease currently. However, most patients could only receive palliative bypass surgery when they were diagnosed. Makarova-Rusher OV et al. reported that only a small percentage of patients with SCC (10.3%) could receive potentially curative surgery, which improved survival \[[@R4]\]. The median survival, 1-year survival, and 2-year survival of recectable SCC were 10, 45.3 and 35.2 months, while that of unrecectable cohort were only 3, 10.3 and 3.7 months. For patients who received complete resections, there were no significant differences in OS of SCC and AC \[[@R4]\]. Other treatments for this disease include systemic chemotherapy, radiotherapy and/or immunotherapy. However, for those unresectable subjects, survival of SCC was worse than that of AC. The median survival, 1-year survival, and 2-year survival of unresectable AC were 5, 17.9 and 5.1 months, which were better than that of unresectable SCC \[[@R4]\]. Cisplatin was used in combinations with 5-FU (three cases) \[[@R5], [@R16], [@R26]\], or gemcitabine (one case) which progressed after 8 weeks and then received 5-FU/leucovorin as second-line therapy for 3months \[[@R15]\]. Gemcitabine has been used solo (two cases) \[[@R14], [@R18]\] or in combination with carboplatin (one case) \[[@R21]\]. Immunotherapy was used in one patient who had a good prognosis after palliative bypass surgery \[[@R19]\]. S-1 (100 mg/day) was also proved to be effective in one patient in the first four courses \[[@R14]\]. One patient who underwent spleno-corporeo-caudal pancreatectomy with pancreatic stump sutures and then received chemotherapy according to the FUFOL regiment (5-FU/leucovorin) was in complete remission after a follow-up period of 26 months \[[@R16]\]. Radiotherapy combined with chemotherapy was also used in some cases. However, there is still no standard therapy regimen established so far.

Cancers containing both squamous and glandular elements are found in many organs, like lung, esophagus, etc. Taking AC and SCC of lung as an example, previous studies proved that AC and SCC present significant differences at both expression and genomic levels \[[@R37]--[@R42]\]. Despite the low incidence of pancreatic SCC, accumulation of tissue samples in the past decades has led to systematic investigations in this rare subtype. After screening 25 SCC samples by using RNA-seq and 71 SCC samples by using mRNA microarray, Peter Bailey et al. identified four core gene expression programmes characterized pancreatic SCC, including gene networks involved in inflammation, hypoxia response, metabolic reprogramming, TGF-β signalling, MYC pathway activation, autophagy and upregulated expression of TP63ΔN and its target genes \[[@R6]\]. By using KEGG pathway assay, we illustrated the participation of these differentially expressed genes in cell signaling transduction network in cancer (Figure [4](#F4){ref-type="fig"}).

To explore the genomic characteristics of SCC, we used a 137-cancer-related gene panel for in-solution hybrid capture accompanied by Illumina paried-end sequencing. For some well-known pancreatic cancer biomarkers \[[@R43]\], we have detected the common and different SNVs in pancreatic ACs, ASCs and SCCs, respectively. For instance, the oncogene KRAS encodes for the membrane-bound GTP-binding protein, which is involved in the signaling pathways mediated by growth factor. In 80%\~90% of patients with pancreatic cancer, KRAS gene is frequently detected to be mutated at codon 12 and sometimes mutated at codons 13 or 61 \[[@R44]--[@R47]\]. In the present study, for the oncogene KRAS, we have detected Gly12Arg mutation in pancreatic ACs, Gly12Asp mutation in SCC of pancreas, while no mutation of KRAS has been detected in pancreatic ASCs (Table [3](#T3){ref-type="table"}). TP53 is encoded by p53 gene which is a tumor suppressor gene mutated in the human cancers \[[@R48]\]. In our analysis, TP53 possessed the same mutation (Pro72Arg) in the three groups. SMAD4 is a tumor suppressor encoded by the *SMAD4* gene located on chromosome 18q. SMAD4 has been detected to possess mutations of Pro292Ser and Arg496His in ASCs and SCCs, respectively, and no mutation of SMAD4 was detected in pancreatic ACs (Table [3](#T3){ref-type="table"}). BRCA2 is involved in the transcriptional regulation, cell growth, chromatin remodeling and DNA damage repair \[[@R49]--[@R54]\]. Pancreatic ACs, ASCs and SCCs shared the common mutation Val2466Ala, while each of them also have some specific mutations (Table [3](#T3){ref-type="table"}). The epidermal growth factor receptor (EGFR) is a glycoprotein involved in several human cancers \[[@R55]\]. We detected a common mutation: Arg521Lys of EGFR in all the three types of tissues, while only ACs and ASCs possessed the Leu861Glu mutation (Table [3](#T3){ref-type="table"}).

Besides the common and specific mutations for the studied biomarkers of pancreatic cancer, we also found some other new specific mutated genes in either pancreatic ACs or SCCs (Table [4](#T4){ref-type="table"}, Table [5](#T5){ref-type="table"}). Nine mutated genes (ABCB1, CSF1R, CYP2C18, FBXW7, ITPA, KIAA0748, SOD2, SULT1A2, ZNF142) did not exist in SCC samples (Table [4](#T4){ref-type="table"}), among which four genes (ABCB1, CYP2C18, SOD2, ZNF142) were mutated exclusively in AC tissues (Highlighted in red in Table [4](#T4){ref-type="table"}). Some of these genes are known to be involved in the regulation of oxidative stress cell death or intrinsic apoptotic signaling pathway (FBXW7, SOD2) and positive regulation of protein tyrosine kinase activity (CSD1R, FBXW7). ABCB1 is involved in multidrug resistance. The protein encoded by this gene is an ATP-dependent drug efflux pump for xenobiotic compounds with broad substrate specificity. It is responsible for decreased drug accumulation in multidrug-resistant cells and often mediates the development of resistance to anticancer drugs. CYP2C18 belongs to cytochrome P450 2C subfamily, which is involved in cancer susceptibility risk \[[@R56]\]. ITPA controls the level of nucleotides including ITP and dITP, which exist in all cells. It has been suggested that the function of this ubiquitous protein family is the elimination of minor potentially mutagenic or clastogenic purine nucleoside triphosphatases from the cell. The mRNA expression level of ITPA was proved to be higher in tumor cells than those in normal tissues, showing preferentially expressed in tumor cells \[[@R57]\]. KIAA0748, also known as TESPA1, is expressed in lymphocytes and is phosphorylated in response to store-operated calcium entry. SULT1A2 which drastically reduces its affinity for the substrate, is supposed to be associated with bladder cancer and breast cancer \[[@R58], [@R59]\]. ZNF142 is related to transcriptional regulation, controlling cell growth, proliferation, differentiation, and apoptosis. We also detected nine mutated genes (C7orf70, DNHD1, KPRP, MDM4, MUC6, OR51Q1, PTPRD, TCF4, TET2) in SCCs or ASCs (Table [5](#T5){ref-type="table"}), among which four genes (DNHD1, OR51Q1, PTPRD, TCF4) were mutated only in SCCs (Highlighted in red in Table [5](#T5){ref-type="table"}). DNHD1 and OR51Q1 are known very little, but a clinical genomics study shows that DNHD1 is harbored independent homozygous mutations in patients with overlapping phenotypes \[[@R60]\]. PTPRD is known to regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. Studies also identified deletion of PTPRD in head and neck SCC \[[@R61]\]. TCF4 encodes transcription factor 4, and is closely related to the canonical Wnt pathway, which plays key roles in development, tissue homeostasis, and cancer. Intriguingly, TET2 is known to be involved in histone H3K4 methylation and DNA demethylation, suggesting that this gene might work in SCC through epigenetic mechanisms. Taking together with previous study \[[@R6]\], the development and progression of pancreatic SCC could be driven by both specific gene mutations and uncontrolled gene expression network.

Previous studies provided many theories concerning the histogenesis of squamous elements of pancreatic SCC. These theories may be summarized as follows: (1) heterotopic or metaplastic squamous epithelium undergoes malignant change due to chronic inflammation, (2) preexisting adenocarcinoma undergoes malignant transformation (malignant metaplasia) into squamous cell carcinoma, (3) SCC that originates from a mixed ASC in which the glandular components are not visible, and (4) a primitive cell capable of differentiating into either squamous or glandular cell carcinoma undergoes malignant change \[[@R22], [@R28], [@R62]--[@R65]\]. Based on the gene expression patterns, Peter Bailey et al., recently found that inflammatory pathway played a vital role in the gene networks of pancreatic SCC \[[@R6]\]. Therefore, this investigation provided the first direct evidence that chronic inflammation could be involved in the development and progression of pancreatic SCC. Since inflammation has been proved to be able to promote the growth and metastasis of pancreatic cancer \[[@R66]\], the participation of inflammatory pathway in pancreatic SCC may explain why this subtype has the worst outcome, comparing to other subtypes \[[@R6]\].

Limited by the rareness of pancreatic SCC tissue samples, our study is just the tip of the iceberg, and further researched need to be undertaken in the future. To the best of our knowledge, our study was the first investigation providing the list of differential mutations in pancreatic AC and SCC, which could provide valuable information for understanding the pathogenesis of pancreatic SCC and for further targeted drug development.

MATERIALS AND METHODS {#s4}
=====================

Tissue specimens {#s4_1}
----------------

The pancreatic tissues were obtained from patients with adenocarcinoma (AC), squamous cell carcinoma (SCC) and adenosquamous carcinoma (ASC) who underwent the surgery of pancreaticoduodenectomy. The diagnosis of AC, SCC and ASC of the pancreas was confirmed by pathological examination. The Formalin Fixed Paraffin Embedded (FFPE) tissue specimens of SCC (2 patients) and ASC (2 patients) were provided by the First Affiliated Hospital of Soochow University and Renji Hospital of Shanghai, while those of AC were taken from 4 patients admitted to the Second Affiliated Hospital of Soochow University. The tissues were fixed in 10% neutral buffered formalin and embedded in paraffin with the FFPE protocol. All human tissue samples were obtained and handled in accordance with an approved Institutional Review Board application (the Committee on Medical Ethics, the First Affiliated Hospital of Soochow University). All experiments were performed in accordance with relevant guidelines and regulations of the Committee on Medical Ethics of the First Affiliated Hospital of Soochow University. All the patients signed an informed consent for participation of the study and the use of their biological tissues. Primary SCC of pancreas was pathologically diagnosed on the basis of finding definite intercellular bridges and/or focal keratin peal formation in the tumor cells.

Immunohistochemistry {#s4_2}
--------------------

All resection specimens were fixed in 10% buffered formalin and paraffin-embedded by routine processing. Sections were cut at 4-μm thickness, heated at 60°C for 30 min, then deparaffinized and hydrated through a series of xylene and alcohol baths. The slides were microwaved with antigen retrieval solution (citrate buffer, pH 6.0, containing 0.3% trisodium citrate and 0.04% citric acid) for 5 min. After replenishment of this solution, the slides were microwaved again for 5 min and then allowed to cool for 20 min. The sections were then rinsed in PBS and immersed in 3% H~2~O~2~ for 15 min to block the endogenous peroxidase. Thereafter, the sections were incubated with 10% bovine serum albumin at room temperature for 1 h to block nonspecific antibodies. Immunohistochemical staining was performed with mouse anti-P63 antibody (Dako, Carpenteria, CA, USA) or mouse anti-CK5/6 antibody (Dako) at room temperature for 2 h. After incubation with the corresponding secondary antibodies for 20 min, the bound complex was visualized using a SuperPicture Polymer Detection Kit (Life Technologies, Valencia, CA, USA).

Extraction of DNA {#s4_3}
-----------------

Genomic DNA was extracted from the FFPE samples using the QIAamp DNA FFPE Tissue Kit (Cat No. 56404, Qiagen, Valencia, CA, USA) according to the manufacturer\'s protocols. 1 μl of DNA was used to measure DNA concentration on a Qubit 2.0 Fluorometer (Life Technologies), and the quality control of DNA was done by running the DNA on a 1% agarose gel.

Library construction {#s4_4}
--------------------

220--320ng of DNA for each sample was used to construct the pre-captured DNA library using DNA Seq Library Preparation Kit-Illumina Compatible (K02422, Gnomegen, San Diego, CA, USA) according to the manufacturer\'s protocol. The fragmented DNA was subsequently end repaired, ligated to adaptors and subjected to PCR amplification with 9 or 11 amplification cycles according to the manufacturer\'s instructions with several purification steps to get library products with different indexes (K02422, Gnomegen). The pre-captured library was purified with Gnome Size Selector (R02424, Gnomegen) and quantified with a Qubit 2.0 Fluorometer (Life Technologies), and quality control was performed by running the purified library on a 1% agaroase gel.

In-solution hybrid capture and illumina sequencing {#s4_5}
--------------------------------------------------

The pre-captured DNA was hybridized to the 137 cancer gene probes (Roche NimbleGen, Madison, Wisconsin, USA) at 47°C for 64--72 h, which can enrich the exonic sequences of 137 cancer-related genes according to the manufacturer\'s protocol from NimbleGen SeqCap EZ Library SR User\'s Guide v3.1 (Roche NimbleGen). The 137 genes that we chose are known to have somatic genomic variants in cancer \[[@R11]--[@R13]\]. These genes contain 2372 exons that encode 433,159 bases. The exome-enriched libraries were sequenced on the Illumina HiSeq 2000 platform with 1000× sequencing depth, and paired-end reads with an average size of 125 bp (PE125) were generated.

Bioinformatic analysis {#s4_6}
----------------------

The sequencing reads were mapped to the reference human genome (UCSC hg19) with BWA \[[@R67], [@R68]\]. We used the quality threshold (-q35) and mismatch penalty (-M) as 3 and -d as 10 to map the unique reads. SNVs (single-nucleotide variants) and InDels (Insertions and Deletions) were subsequently called using the Genome Analysis Toolkit \[[@R69]\] with default parameters \[[@R70]\]. The functions of the specific mutated genes in either AC or SCC were annotated and analyzed with the EnrichR tool \[[@R71]\]. Briefly, the list of the specific mutated genes was submitted to EnrichR website: <http://amp.pharm.mssm.edu/Enrichr/>, and searched for the databases of Gene Ontology (GO) involving molecular functions or biological processes. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database (<http://www.genome.jp/kegg/pathway.html>) was used for pathway analysis and mapping \[[@R72]\].
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